At a Glance
- Global Multiple Sclerosis market projected to reach $30.6 billion by 2034.
- New therapies and generic approvals are driving market expansion.
- Regulatory activity remains high for multiple sclerosis treatments.
The global Multiple Sclerosis (MS) market is anticipated to experience substantial expansion, with projections indicating a rise from USD 21,831 million in 2025 to USD 30,597 million by 2034. This growth, representing a compound annual growth rate (CAGR) of 3.8%, is expected across key markets including the United States, EU4, the United Kingdom, and Japan. The market trajectory is influenced by ongoing advancements in treatment options and a dynamic regulatory landscape.
Market Expansion and Treatment Pipeline
The Multiple Sclerosis market is poised for considerable expansion, with projections indicating a substantial increase driven by a pipeline of new treatments and significant regulatory milestones. The market, encompassing the 7MM (United States, Germany, Spain, Italy, France, United Kingdom, and Japan), was valued at USD 21,831 million in 2025. It is forecast to grow to USD 30,597 million by 2034, reflecting a compound annual growth rate of 3.8% and a steady upward trend in therapeutic availability.
Specifically, the United States market alone accounted for approximately USD 16,000 million in 2024. This segment is expected to grow further with the introduction of various emerging therapies. Regulatory bodies have maintained strong momentum in the neurology sector, evidenced by numerous reviews and development milestones reported across neurological disorders, including continued advancements in the MS pipeline. Companies are actively advancing late-stage candidates and preparing for upcoming regulatory filings.
Prominent industry players such as Biogen, Sanofi, and GSK plc are among the entities actively contributing to the evolving treatment landscape. Other firms, including Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GeNeuro, Immunic Therapeutics, and Hoffman-La-Roche, are also engaged in developing new therapeutic solutions. This collective industry effort underscores a sustained focus on addressing the complex challenges associated with Multiple Sclerosis.
Regulatory Approvals and Development Milestones
Recent regulatory activities highlight significant progress in bringing new and generic MS treatments to market. In January 2026, the FDA approved ScinoPharm Taiwan's glatiramer acetate injection for the treatment of relapsing multiple sclerosis, marking a notable approval for a complex generic injectable. Following this, in December 2025, Lupin received tentative approval from the U.S. FDA for its bioequivalent siponimod tablets. This generic version of Mayzent is intended for treating clinically isolated syndrome, relapsing-remitting MS, or active secondary progressive MS.
Further contributing to generic availability, Zydus Lifesciences partnered with Netherlands-based Synthon BV in September 2025 to launch a generic version of ZEPOSIA (ozanimod) in the US market. While this generic received tentative FDA approval, indicating it met safety, efficacy, and quality standards, its market entry awaits the expiration of existing patent protections. Separately, Sanofi encountered a three-month delay in its FDA approval decision for tolebrutinib, an investigational MS drug, in September 2025, although the drug later secured Priority Review status in March 2025 for non-relapsing secondary progressive MS.
Beyond drug approvals, several companies are exploring novel approaches and diagnostics. Ashvattha Therapeutics announced in June 2025 that its nanomedicines could be tailored to visualize neuroinflammation in MS patients. IASO Bio showcased encouraging results for Equecabtagene Autoleucel in MS patients from an IIT study. These developments showcase the businesses navigating complex global economic shifts as they invest in long-term research and development.
Immunic Therapeutics, despite a Phase II trial not meeting its primary endpoint, intends to continue developing vidofludimus calcium (IMU-838) for MS, citing a slight benefit in exploratory measures. Telomir Pharmaceuticals reported in June 2025 that Telomir-1 resets the body's epigenetic clock and reverses DNA methylation in Werner Syndrome patients, a finding with potential broader implications for age-related conditions. TG Therapeutics also announced upcoming data presentations on BRIUMVI for Multiple Sclerosis in May 2025.
The Multiple Sclerosis market is clearly on a path of significant expansion, fueled by both the introduction of new generic alternatives and a pipeline of innovative therapies. With continued regulatory support and ongoing research, the coming decade is expected to bring more options for patients globally. This sustained activity reflects a concentrated effort to address unmet medical needs and improve patient outcomes in MS.